Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
Dr RR Baliga's "Got Knowledge Doc" Podkast
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The AZALEA–TIMI 71 trial compared abelacimab, a monoclonal antibody targeting factor XI, with rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk.
🚨 New study: Abelacimab vs. Rivaroxaban in AFib 📊
✅ 62-69% lower bleeding risk than rivaroxaban ✅ 5x lower GI bleeding ⚠️ Slightly higher ischemic stroke rates
A promising safer anticoagulant? 🔬 More data needed! #CardioTwitter #CardioEd #MedEd
Abelacimab significantly reduced bleeding compared to rivaroxaban (HR: 0.38 for 150 mg, 0.31 for 90 mg, p
Gastrointestinal bleeding was five times lower with abelacimab. However, ischemic stroke rates were slightly higher.
The study highlights abelacimab's potential as a safer anticoagulant, with further phase 3 trials (LILAC–TIMI 76) needed to assess stroke prevention efficacy.